TY - JOUR
T1 - Mediterranean diet and physical activity decrease the initiation of cardiovascular drug use in high cardiovascular risk individuals
T2 - A cohort study
AU - Ribó‐coll, Margarita
AU - Castro‐barquero, Sara
AU - Lassale, Camille
AU - Sacanella, Emilio
AU - Ros, Emilio
AU - Toledo, Estefanía
AU - Sorlí, José V.
AU - Díaz‐lópez, Andrés
AU - Lapetra, José
AU - Muñoz‐bravo, Carlos
AU - Arós, Fernando
AU - Fiol, Miquel
AU - Serra‐majem, Lluis
AU - Pinto, Xavier
AU - Castañer, Olga
AU - Fernández‐lázaro, César I.
AU - Portolés, Olga
AU - Babio, Nancy
AU - Estruch, Ramón
AU - Hernáez, Álvaro
N1 - Funding Information:
Funding: This work was supported by grants of the Official College of Pharmacists of Barcelona (Col∙legi Oficial de Farmacèutics de Barcelona, COFB), Instituto de Salud Carlos III [OBN17PI02, CB06/03/0019, CB06/03/0028, CD17/00122 to A.H.], Agència de Gestió d’Ajuts Universitaris i de Recerca [2017 BP 00021 to C.L., 2017 SGR 222], the Spanish Ministry of Science, Innovation, and Universities [FPU17/00785 to S.C.‐B.], and the European Regional Development Fund (ERDF). The funders had no role in study design, data collection and analysis, decision to publish, or prepara‐ tion of the manuscript.
Funding Information:
Acknowledgments: A full list of names of all study collaborators is available in the Appendix I. Centro de Investigación Biomédica En Red de Fisiopatología de la Obesidad y Nutrición (CIBE‐ ROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain, and financed by the Eu‐ ropean Regional Development Fund.
Funding Information:
Conflicts of Interest: E.R. reports personal fees, grants, and nonfinancial support from the Califor‐ nia Walnut Commission and Alexion; personal fees and nonfinancial support from Danone; and nonfinancial support from the International Nut Council. F.A. reports receiving personal fees from Menarini and AstraZeneca. L.S.‐M. reports being a board member of the Mediterranean Diet Foundation and the Beer and Health Foundation. X.P. reports being a board member of and ob‐ taining lecture fees and grants from Ferrer International; being a board member of and obtaining grants from the Residual Risk Reduction Initiative Foundation; personal fees from Abbott Labora‐ tories; lecture fees and grants from Merck and Roche; lecture fees from Danone, Esteve, Menarini, Mylan, LACER, and Rubio Laboratories; and grants from Sanofi, Kowa, Unilever, Boehringer Ingelheim, and Karo Bio. R.E. reports being a board member of the Research Foundation on Wine and Nutrition, the Beer and Health Foundation, and the European Foundation for Alcohol Re‐ search; and receiving personal fees from KAO Corporation; lecture fees from Instituto Cervantes, Fundación Dieta Mediterranea, Cerveceros de España, Lilly Laboratories, AstraZeneca, and Sanofi; and grants from Novartis, Amgen, Bicentury, and Grand Fountaine. The rest of the authors have nothing to disclose.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/3
Y1 - 2021/3
N2 - Our aim was to assess whether long‐term adherence to a Mediterranean diet (MedDiet) and leisure‐time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non‐medicated at baseline: glucose‐lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One‐point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose‐lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin (HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56–0.84]). LTPA was non‐linearly related to a delayed initiation of glucose‐lowering, antihyper-tensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180– 360 metabolic equivalents of task‐min/day). Both combined were synergistically associated with a decreased onset of glucose‐lowering drugs (p‐interaction = 0.04), antihypertensive drugs (p‐interac-tion < 0.001), vitamin K antagonists (p‐interaction = 0.04), and cardiac glycosides (p‐interaction = 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk of initiating cardiovascular‐related medications.
AB - Our aim was to assess whether long‐term adherence to a Mediterranean diet (MedDiet) and leisure‐time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non‐medicated at baseline: glucose‐lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One‐point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose‐lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin (HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56–0.84]). LTPA was non‐linearly related to a delayed initiation of glucose‐lowering, antihyper-tensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180– 360 metabolic equivalents of task‐min/day). Both combined were synergistically associated with a decreased onset of glucose‐lowering drugs (p‐interaction = 0.04), antihypertensive drugs (p‐interac-tion < 0.001), vitamin K antagonists (p‐interaction = 0.04), and cardiac glycosides (p‐interaction = 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk of initiating cardiovascular‐related medications.
KW - Antianginal drugs
KW - Antihypertensive drugs
KW - Antiplatelet drugs
KW - Cardiac glycosides
KW - Fibrates
KW - Glucose‐lowering drugs
KW - Mediterranean diet
KW - Physical activity
KW - Statins
KW - Vitamin K epoxide reductase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85102050342&partnerID=8YFLogxK
U2 - 10.3390/antiox10030397
DO - 10.3390/antiox10030397
M3 - Article
AN - SCOPUS:85102050342
SN - 2076-3921
VL - 10
SP - 1
EP - 15
JO - Antioxidants
JF - Antioxidants
IS - 3
M1 - 397
ER -